|
| Study | Drug tested and mean-range dosage | Study design | Study group and duration | Findings |
|
| Antidepressants in GD |
| Hollander et al. 2000 [11] | Fluvoxamine (SSRI)
mean dose 195 mg/day | Double-blind cross-over
placebo-controlled | 15 patients
for 16 weeks | Fluvoxamine is superior to placebo |
| Blanco et al. 2002 [20] | Fluvoxamine (SSRI)
mean dose 200 mg/day | Double-blind
placebo-controlled | 32 patients
for 6 months | Fluvoxamine is not significantly superior to placebo |
| Kim et al. 2002 [12] | Paroxetine (SSRI)
20–60 mg/day | Double-blind
placebo-controlled | 45 patients
for 8 weeks | Paroxetine is superior to placebo |
|
Grant and Potenza 2003 [23] | Paroxetine (SSRI)
10–60 mg/day | Double-blind
placebo-controlled | 76 patients
for 16 weeks | Paroxetine is not significantly superior to placebo |
| Saiz-Ruiz et al. 2005 [14] | Sertraline (SSRI)
50–150 mg/day | Double-blind
placebo-controlled | 60 patients
for 6 months | Sertraline is not significantly superior to placebo |
| Grant et al. 2006 [13] | Escitalopram (SSRI)
mean dose 25 mg/day | Open-label
for 12 weeks
Double-blind
placebo-controlled
for 8 weeks | 13 patients
with comorbid anxiety
for 20 weeks | Escitalopram is superior to placebo |
| Black et al. 2007 [26] | Bupropion (NDRI)
mean dose 325 mg/day | Double-blind
placebo-controlled | 39 patients
for 12 weeks | Bupropion is not significantly superior to placebo |
|
